文献速递神经PETCTMR

Centiloid量表淀粉样蛋白PET定量在临床实践中的附加价值

Added Value of Amyloid PET Quantification with the Centiloid Scale in Clinical Practice.
PubMed 文献 · AJNR Am J Neuroradiol · 2025-10-01

回顾167例临床淀粉样蛋白脑PET/CT,3名读者盲法视觉判读为阴性、阳性或不确定,另2名读者用MIMNeuro生成Centiloid评分和区域标准化摄取比值;全体读者一致阳性53例、一致阴性62例,一致率69.46%;视觉阳性最低Centiloid评分为57,一致阴性最佳切点为CL<3.6,一致视觉阳性最佳切点为CL≥28.8。

要点

  • 3名读者一致阳性53例(31.74%)、一致阴性62例(37.13%),一致率69.46%。
  • 视觉阳性最低CL评分为57,至少1个不确定评分的最低CL评分为11。
  • 一致阴性最佳切点CL<3.6,一致视觉阳性最佳切点CL≥28.8。

核心结论

  • 本研究提示淀粉样蛋白PET视觉判读在淀粉样变较轻但累及多个区域(CL 40至59)时可能不敏感,CL量表定量可能有助于指导考虑抗淀粉样蛋白疾病修饰治疗的轻度淀粉样变患者的治疗。

研究设计与样本

  • 回顾性分析167例临床淀粉样蛋白脑PET/CT扫描,3名读者盲于原始报告进行视觉判读,2名额外读者用MIMNeuro生成CL评分和区域标准化摄取比值,以CL≥40为阳性扫描切点。

诊断标准与关键数值

  • 视觉判读分为阴性(0)、阳性(1)、不确定(2);CL阳性切点为CL≥40,CL阴性扫描为CL<10;一致阴性最佳切点CL<3.6,一致视觉阳性最佳切点CL≥28.8;阳性一致κ=0.62,阴性一致κ=0.66,不确定一致κ=0.17。

临床应用与阅片要点

  • 作者认为,鉴于抗淀粉样蛋白单克隆治疗用于早期阿尔茨海默病,可靠检测淀粉样变对患者照护至关重要;CL量表定量可能有助于指导考虑抗淀粉样蛋白疾病修饰治疗的轻度淀粉样变患者。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

BACKGROUND AND PURPOSE: The objectives for amyloid brain PET/CT and PET/MRI fusion images are to determine the agreement between visual interpretations of amyloid PET and to compare the results of visual interpretation with quantitative analysis as measured by the Centiloid (CL) scale.

MATERIALS AND METHODS: One hundred sixty-seven clinical amyloid brain PET/CT scans were reviewed by 3 readers blinded to the original reports. Readers interpreted the amyloid PET scans as negative (0), positive (1), or indeterminate (2) for amyloid deposition. For quantitative analysis, 2 additional readers analyzed amyloid PET images using MIMNeuro to generate CL scores and regional standardized uptake ratios. Reader agreement was determined for visual and quantitative assessment. Using positive scan cutoffs of CL ≥ 40, we determined visual assessment-versus-quantitative assessment for scans consistently interpreted as positive by all 3 readers and for each reader.

RESULTS: Fifty-three scans (31.74%) were rated amyloid-positive by all readers, while 62 scans (37.13%) were rated as amyloid-negative by all readers. The remaining 52 scans had inconsistent ratings with an agreement rate of 69.46%. Most (99/167; 59.28%) scans had CL scores above the CL-positive cutoff (CL ≥ 40), and 47/167 (28.14%) were CL-negative scans (CL <10). The lowest CL score to achieve visual positivity among all 3 readers was 57, while the lowest CL score to receive at least 1 indeterminate score was 11. The readers had a high degree of interreader reliability when rating scans as either positive (κ = 0.62) or negative (κ = 0.66) but were inconsistent when rating scans as indeterminate (κ = 0.17). Optimal cut-points were CL <3.6 for consistent negative and CL ≥28.8 for consistent visual positivity.

CONCLUSIONS: Given the emergence of antiamyloid monoclonal therapies for early-stage Alzheimer disease, reliable detection of amyloidosis is critical for patient care. This study suggests that visual reads of amyloid PET may be insensitive when amyloidosis is milder but are spread across multiple regions (CL ranging from 40 to 59). Quantification of amyloid PET using the CL scale may help guide treatment of patients with mild amyloidosis who are under consideration for antiamyloid disease-modifying therapeutics.

来源:AJNR Am J Neuroradiol,查看原文。版权归原作者所有。

引用

  1. Vijayashankar A, Keir G, Sagnelli M, et al. Added Value of Amyloid PET Quantification with the Centiloid Scale in Clinical Practice. AJNR Am J Neuroradiol. 2025. PMID: 40968015. doi:10.3174/ajnr.A8850

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。